Mizuho initiated coverage of Medline (MDLN) with an Outperform rating and $48 price target The firm says the company’s “hybrid” manufacturing and wholesale distribution approach to the medical-surgical supply market has led to large market share gains over the past 10 years. Medline is only in the “middle innings” of this playbook, suggesting another decade or more of potential above-industry-average growth opportunity, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDLN:
- Medline: Durable Moat, Secular Tailwinds, and Attractive Valuation Support Buy Rating
- Medline: Durable Growth, Expanding Market Share, and Margin Upside Support Buy Rating and $46 Target
- Medline: Vertically Integrated Growth Leader With Prime Vendor Advantage Supporting Buy-Rated Risk/Reward
- Medline, Inc. Class A: Leveraging a ‘Costco of Healthcare’ Model for Visible Growth, Margin Expansion, and Upside Potential
- Medline, Inc. Class A: Prime Vendor Wins, Branded Mix Shift, and Margin Expansion Support Buy Rating and Premium Valuation